Tonix Pharmaceuticals Holding Corp. (TNXP) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 6 Buy, 1 Hold.
Analysts estimate Earnings Per Share (EPS) of $-113.50 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-3,504.00 vs est $-113.50 (missed -2987.2%). 2025: actual $-14.57 vs est $-13.43 (missed -8.5%). Analyst accuracy: 48%.
TNXP Analyst Ratings
Buy
Based on 7 analysts giving stock ratings to Tonix Pharmaceuticals Holding Corp. in the past 3 months
EPS Estimates — TNXP
48%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$3,504.00
vs Est –$113.50
▼ 96.8% off
2025
Actual –$14.57
vs Est –$13.43
▼ 7.8% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — TNXP
76%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.010B
vs Est $0.013B
▼ 26.8% off
2025
Actual $0.013B
vs Est $0.010B
▲ 20.4% off
Revenue Trend
Moderate revenue growth trend. Analysts expect stable revenue going forward.
